Novartis Q4 Preview: Launches Likely To Deliver
Beovu Sales Forecast To Fly
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
